Sorafenib Versus Capecitabine in the Management of advanced Hepatocellular Carcinoma

Abdelwahab, Manal M.; Mohammed, Shaker; Abdel-Wahab, Sherif; Elbassiouny, M.; Ellithy, Mahmoud; Abdelrhman, O.

doi:10.1016/s0923-7534(20)33239-7

Cited by 11 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Capecitabine, a prodrug of 5-fluorouracil (5-FU) metabolized to the active drug preferentially in liver and tumor tissue by thymidine phosphorylase (Walko and Lindley 2005), has been tested as first-and second-line treatment for HCC by some studies, using either the conventional or metronomic approach (Patt et al 2004;Lee et al 2009;Farrag 2012;He et al 2013;Abdel-Rahman et al 2013;Brandi et al 2013;Granito et al 2015;Murer et al 2016;Casadei Gardini et al 2017). The obtained results are sparse and rather conflicting, and only one of these studies compared capecitabine with best supportive care (BSC) in the setting of second-line therapy (Casadei Gardini et al 2017).…”

Section: Introductionmentioning

confidence: 99%

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

Trevisani

Brandi

Garuti

et al. 2017

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

Trevisani

Brandi

Garuti

et al. 2017

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Abdel-Rahman et al [30], compared capecitabine to sorafenib and found that hand-foot skin reaction was more frequent in the sorafenib group, hyperbilirubinemia was more common in the capecitabine group, and diarrhea was equivalent between both groups.…”

Section: Discussionmentioning

confidence: 99%

Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma

Khedr

Elzawawy

Gowil

et al. 2016

Korean J Clin Oncol

View full text Add to dashboard Cite

Purpose: We evaluated oral metronomic capecitabine (MC) compared to intravenous doxorubicin in patients with advanced or metastatic hepatocellular carcinoma (HCC). Methods: From January 2013 to December 2015, patients with Child-Pugh class A or early B were randomized either to MC group (500 mg twice daily continuously) or doxorubicin group (60 mg∕m 2 every 21 days). Results: Forty patients were included in each group. The baseline clinical characteristics of the enrolled patients were well balanced between the two groups. No complete response (CR) was reported in either group. In MC group, 2 patients (5%) had partial response (PR), 25 patients (62.5%) stable disease (SD) and 27 patients (67.5%) had disease control. In doxorubicin group, 4 patients (10%) achieved PR, 24 patients (60%) SD and 28 patients (70%) had disease control. The 6 months overall survival (OS) was 77.5% for MC and 75% for doxorubicin. The one year OS was 47.5% for MC and 42.5% for doxorubicin (P= 0.521). The median OS survival was 10.2 months for MC and 9.6 months for doxorubicin (95% confidence interval, 3.2-6.5). The 6 month progression-free survival (PFS) was 45% for MC and 50% for doxorubicin. The one year PFS was 12.5% for MC and 7.5% for doxorubicin (P= 0.289). The median time to progression was 3.4 months for MC and 3.1 months for doxorubicin. On multivariate analysis no significant impact for tumor stage, previous transhepatic arterial chemoembolization, portal vein thrombosis or median baseline alpha fetoprotein on OS. Conclusion: MC showed response rate and survival outcome comparable to doxorubicin in advanced HCC but with a more favorable toxicity profile.

show abstract

“…The superiority of single-agent sorafenib over capecitabine was confirmed in a single-center, open-label, phase II trial by Abdel-Rahman et al [55]. The study enrolled 52 treatment-naive HCC patients who were randomized to get administered sorafenib (400 mg twice daily) or capecitabine (100 mg mg/m 2 twice daily).…”

Section: Capecitabinementioning

confidence: 95%

Past, Present, and Future Perspectives on the Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) — A Comprehensive Review

Abu‐Zaid¹,

Alkhatib²,

Hoilat³

et al. 2015

Recent Advances in Liver Diseases and Surgery

View full text Add to dashboard Cite

Hepatocellular carcinoma HCC is the fifth most frequent cancer, the third leading cause of cancer-related mortality, and the first leading cause of death in patients with cirrhosis. Management of primary locally advanced, inoperable, recurrent or metastatic HCC is very challenging and continues to be a topic of controversy. Herein, we shed light on the past, present, and future perspectives on the systemic therapy hormonal therapy, cytotoxic chemotherapy, and novel molecularly targeted therapy for management of patients with advanced HCC.

show abstract

Sorafenib Versus Capecitabine in the Management of advanced Hepatocellular Carcinoma

Cited by 11 publications

References 0 publications

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma

Past, Present, and Future Perspectives on the Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) — A Comprehensive Review

Contact Info

Product

Resources

About